JAMA Ophthalmology : Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema

JAMA Network - En podkast av The JAMA Network

Prøv Podimo gratis i hele 60! dager!

Prøv Podimo gratis i hele 60! dager!

I Podimo finner du eksklusive podkaster og bestselgende lydbøker tilpasset dine ører

 Reklame

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.

Visit the podcast's native language site